Gastric/Stomach Cancer
Show Only Open Trials
1.
Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Metastatic Epithelial Cancer
2.
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
- Study Status: Open to Enrollment
- Sponsor: Hoffmann-La Roche/Genentech
- Disease Status and/or Stage: Advanced or Metastatic HER2-Positive Gastric or GEJ Cancer
- Protocol ID: BO27952
3.
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Gastric or Gastroesophageal (GEJ) Cancer
4.
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
- Study Status: Open to Enrollment
- Sponsor: Genentech
- Protocol ID: YO28252
5.
A Study of Trastuzumab in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
- Study Status: Open to Enrollment
- Sponsor: Genentech/Roche
- Disease Status and/or Stage: Metastatic Gastric Cancer
6.
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)
7.
A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer
8.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Open to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
